Wockhardt secures Indian market authorization for its breakthrough antibiotic, ZAYNICH®, treating complicated urinary tract infections.

Wockhardt LimitedWOCKPHARMA · Filed with the exchange

This first-in-class drug demonstrated superior efficacy in trials, targeting critical resistant infections.

No comments yet. Be the first.

More from Wockhardt Limited

Free

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

No card needed. Takes about a minute.